Preliminary data of anchored canine IL-12 (cANK-101) in dogs with malignant melanoma demonstrates tolerable safety and early signs of biologic activity. Human ANK-101 is an IL-12- based anchored immunotherapy with IND submission planned for late 2023 BOSTON, MA, April...

Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced the appointment of Stephen Gorgol as chief financial officer. Mr. Gorgol, a proven financial leader within the biotech industry, joins...

Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that is has entered into a strategic collaboration with the Lung Cancer Initiative (LCI) at Johnson & Johnson*. The collaboration will...

Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that Leisha A. Emens, M.D., Ph.D., has been appointed as senior vice president, translational research. Dr. Emens is an experienced...

Data to be presented during Society for Immunotherapy of Cancer 37th Annual Meeting BOSTON — Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that new, preclinical data highlighting the...

BOSTON, Mass.--(BUSINESS WIRE)— Ankyra Therapeutics, a company developing targeted immune potentiating agents for the treatment of cancer, today announced the appointment of Joseph J. Elassal, M.D., as chief medical officer. Dr. Elassal will fill the role formerly...